Diabetes and Chronic Kidney Disease Management: A Practical Primary Care Approach

The American Diabetes Association (ADA) Standards of Care in Diabetes – 2026 mark a decisive shift in the management of patients with diabetes and chronic kidney disease (CKD). For primary care physicians (PCPs), who are often the first to detect and manage early kidney dysfunction, the updated guidance calls for earlier and more frequent CKD screening, greater emphasis on cardiovascular and renal protection—not just glycemic control—and increased focus on multidisciplinary, team-based care.

CKD affects an estimated 20% to 40% of patients with diabetes and significantly increases cardiovascular (CV) risk. This dual burden reinforces the central role of primary care in identifying disease early, initiating therapy, and coordinating care across specialties. “Earlier recognition and treatment before advanced disease develops can meaningfully improve patient outcomes,” stresses Elizabeth Pabon-Vazquez, MD, a nephrologist with Cleveland Clinic Weston Hospital.

Earlier Detection, More Actionable Screening

The latest ADA standards recommend routine screening with urinary albumin-to-creatinine ratio (uACR) and estimated glomerular filtration rate (eGFR) in all patients with type 2 diabetes at diagnosis and in those with type 1 diabetes after five years. This proactive approach allows for timely intervention before irreversible damage occurs.

Screening frequency should be increased for patients at higher risk, including those with longer diabetes duration, poor glycemic control, hypertension, or a family history of kidney disease. Early detection through uACR and eGFR testing enables clinicians to stage CKD accurately and tailor treatment plans to individual patient needs.

Shifting Focus: Beyond Glycemic Control

Whereas maintaining optimal blood glucose levels remains important, the 2026 ADA Standards place greater emphasis on therapies that provide proven cardiovascular and renal benefits. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are now recommended as foundational treatments for many patients with type 2 diabetes and CKD, regardless of A1C levels, due to their demonstrated ability to slow kidney function decline and reduce heart failure and major adverse cardiovascular events.

These medications perform through multiple mechanisms—reducing intraglomerular pressure, decreasing inflammation and oxidative stress, and promoting weight and blood pressure control—making them invaluable tools in slowing CKD progression. Clinicians should assess eligibility and initiate these therapies early, barring contraindications.

Multidisciplinary, Team-Based Care

Managing diabetes and CKD effectively requires coordination among primary care providers, endocrinologists, nephrologists, dietitians, pharmacists, and diabetes educators. The ADA Standards advocate for structured communication protocols and shared care plans to ensure consistency in monitoring, medication management, and patient education.

Team-based approaches improve adherence to screening and treatment regimens, reduce therapeutic inertia, and help address barriers such as medication cost, access to care, and health literacy. Integrating behavioral health support is as well critical, as the psychological burden of managing two chronic conditions can significantly impact self-care behaviors.

Patient-Centered Education and Self-Management

Empowering patients with knowledge about their condition is essential for long-term success. Education should cover the link between diabetes and kidney disease, the importance of regular monitoring, medication adherence, dietary modifications (including sodium and protein intake guidance), and recognition of warning signs such as swelling, fatigue, or changes in urination.

When patients understand how their actions directly influence kidney health, they are more likely to engage in preventive behaviors. Visual aids, teach-back methods, and culturally appropriate resources enhance comprehension and retention, particularly in diverse populations.

Addressing Disparities in Care

Disparities in CKD screening and treatment persist among racial and ethnic minority groups, rural populations, and individuals with limited socioeconomic resources. The ADA Standards urge healthcare systems to implement equity-focused strategies, such as point-of-care testing in community settings, telehealth expansion, and outreach programs tailored to underserved communities.

Collecting and analyzing disaggregated data on screening rates and outcomes can help identify gaps and guide quality improvement initiatives. Partnering with community health workers and local organizations strengthens trust and improves access to preventive services.

Conclusion

The 2026 ADA Standards of Care reflect a paradigm shift toward proactive, holistic management of diabetes and CKD. By prioritizing early detection, utilizing kidney- and heart-protective medications, fostering team-based care, and centering patient education and equity, primary care providers can significantly alter the trajectory of these interconnected conditions.

As Dr. Pabon-Vazquez emphasizes, intervening early offers the best opportunity to preserve kidney function, reduce cardiovascular risk, and improve quality of life. With consistent application of these evidence-based strategies, the goal of preventing or delaying end-stage kidney disease in people with diabetes is increasingly attainable.

Sources: American Diabetes Association Standards of Care in Diabetes – 2026; Cleveland Clinic Consult QD publications on diabetes and chronic kidney disease management (April 16, 2026 and September 1, 2023).